

Neeraj Agarwal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7696248/publications.pdf>

Version: 2024-02-01

102
papers

7,382
citations

136950

32
h-index

58581

82
g-index

104
all docs

104
docs citations

104
times ranked

8396
citing authors

#	ARTICLE	IF	CITATIONS
1	Survival of Patients with Metastatic Prostate Cancer After Disease Progression on an Androgen Receptor Axis-Targeted Therapy Given in the Metastatic Castration-Sensitive Versus Metastatic Castration-Resistant Prostate Cancer Setting. <i>European Urology Focus</i> , 2023, 9, 106-109.	3.1	3
2	Recent Advances in the Management of Metastatic Prostate Cancer. <i>JCO Oncology Practice</i> , 2022, 18, 45-55.	2.9	75
3	Enzalutamide versus bicalutamide in patients with nonmetastatic castration-resistant prostate cancer: a prespecified subgroup analysis of the STRIVE trial. <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 363-365.	3.9	5
4	Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC. <i>Future Oncology</i> , 2022, 18, 35-45.	2.4	4
5	A phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer. <i>Future Oncology</i> , 2022, 18, 1185-1198.	2.4	10
6	Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. <i>Future Oncology</i> , 2022, 18, 425-436.	2.4	28
7	Real-world patient characteristics associated with survival of 2 years or more after radium-223 treatment for metastatic castration-resistant prostate cancer (EPIX study). <i>Prostate Cancer and Prostatic Diseases</i> , 2022, 25, 306-313.	3.9	5
8	Current and emerging role of sacituzumab govitecan in the management of urothelial carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2022, 22, 335-341.	2.4	8
9	Efficacy and safety exposure-response relationships of apalutamide in patients with metastatic castration-sensitive prostate cancer: results from the phase 3 TITAN study. <i>Cancer Chemotherapy and Pharmacology</i> , 2022, 89, 629-641.	2.3	6
10	Orteronel for Metastatic Hormone-Sensitive Prostate Cancer: A Multicenter, Randomized, Open-Label Phase III Trial (SWOG-1216). <i>Journal of Clinical Oncology</i> , 2022, 40, 3301-3309.	1.6	14
11	First-line Systemic Treatment of Recurrent Prostate Cancer After Primary or Salvage Local Therapy: A Systematic Review of the Literature. <i>European Urology Oncology</i> , 2022, 5, 377-387.	5.4	4
12	Association Between Sites of Metastasis and Outcomes With Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma. <i>Clinical Genitourinary Cancer</i> , 2022, 20, e440-e452.	1.9	10
13	Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). <i>Lancet Oncology</i> , 2022, 23, 899-909.	10.7	26
14	Tumor Frameshift Mutation Proportion Predicts Response to Immunotherapy in Mismatch Repair-Deficient Prostate Cancer. <i>Oncologist</i> , 2021, 26, e270-e278.	3.7	33
15	Baseline Circulating Tumor Cell Count as a Prognostic Marker of PSA Response and Disease Progression in Metastatic Castrate-Sensitive Prostate Cancer (SWOG S1216). <i>Clinical Cancer Research</i> , 2021, 27, 1967-1973.	7.0	18
16	A Randomized Phase II Study of Androgen Deprivation Therapy with or without Palbociclib in RB-positive Metastatic Hormone-Sensitive Prostate Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 3017-3027.	7.0	19
17	Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database. <i>Journal of Clinical Oncology</i> , 2021, 39, 5072-5072.	1.6	17
18	Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings. <i>Journal of Clinical Oncology</i> , 2021, 39, 5074-5074.	1.6	18

#	ARTICLE	IF	CITATIONS
19	Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis.. Journal of Clinical Oncology, 2021, 39, 5073-5073.	1.6	10
20	Complementary Role of Circulating Tumor DNA Assessment and Tissue Genomic Profiling in Metastatic Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 4807-4813.	7.0	9
21	Identification of Somatic Gene Signatures in Circulating <scp>Cell-Free DNA</scp> Associated with Disease Progression in Metastatic Prostate Cancer by a Novel Machine Learning Platform. Oncologist, 2021, 26, 751-760.	3.7	9
22	Differential Activity of PARP Inhibitors in <i>BRCA1</i>- Versus <i>BRCA2</i>-Altered Metastatic Castration-Resistant Prostate Cancer. JCO Precision Oncology, 2021, 5, 1200-1220.	3.0	17
23	Apalutamide in Patients With Metastatic Castration-Sensitive Prostate Cancer: Final Survival Analysis of the Randomized, Double-Blind, Phase III TITAN Study. Journal of Clinical Oncology, 2021, 39, 2294-2303.	1.6	218
24	Drug Development for Prostate Cancer with Biochemical Recurrence: Trials and Tribulations. European Urology Oncology, 2021, 4, 553-557.	5.4	0
25	TROPHY-U-01: A Phase II Open-Label Study of Sacituzumab Govitecan in Patients With Metastatic Urothelial Carcinoma Progressing After Platinum-Based Chemotherapy and Checkpoint Inhibitors. Journal of Clinical Oncology, 2021, 39, 2474-2485.	1.6	250
26	Treatment Pattern and Outcomes with Systemic Therapy in Men with Metastatic Prostate Cancer in the Real-World Patients in the United States. Cancers, 2021, 13, 4951.	3.7	19
27	Drug development in metastatic prostate cancer: lessons from ACIS. Lancet Oncology, The, 2021, 22, 1487-1488.	10.7	0
28	Nature versus Nurture: Investigating Racial Disparity in Advanced Prostate Cancer. Oncologist, 2021, 26, 904-905.	3.7	1
29	Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study. Journal of Clinical Oncology, 2021, 39, 3725-3736.	1.6	69
30	Radium-223 Plus Enzalutamide Versus Enzalutamide in Metastatic Castration-Refractory Prostate Cancer: Final Safety and Efficacy Results. Oncologist, 2021, 26, 1006-e2129.	3.7	13
31	Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer. Drugs, 2021, 81, 191-206.	10.9	11
32	Patterns of treatment in metastatic renal cell carcinoma for older versus younger patients. Journal of Geriatric Oncology, 2020, 11, 724-726.	1.0	2
33	PARP inhibitors in castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2020, 24, 100199.	1.7	12
34	Clinical activity of pembrolizumab in metastatic prostate cancer with microsatellite instability high (MSI-H) detected by circulating tumor DNA. , 2020, 8, e001065.		70
35	PARP Inhibitors in Prostate Cancer: A Promise Delivered. European Urology Oncology, 2020, 3, 612-614.	5.4	2
36	Improvement in overall survival with Apalutamide, Darolutamide and Enzalutamide in patients with non-metastatic castration-resistant prostate cancer. Cancer Treatment and Research Communications, 2020, 25, 100205.	1.7	3

#	ARTICLE	IF	CITATIONS
37	Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 383, 2345-2357.	27.0	440
38	Pan-Cancer Analysis of <i>BRCA1</i> and <i>BRCA2</i> Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity. <i>JCO Precision Oncology</i> , 2020, 4, 442-465.	3.0	103
39	Advanced Prostate Cancer: Treatment Advances and Future Directions. <i>Trends in Cancer</i> , 2020, 6, 702-715.	7.4	122
40	Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. <i>Cancer Management and Research</i> , 2020, Volume 12, 3741-3749.	1.9	15
41	Potential Roles for PD-1 Inhibition and Cabozantinib in Patients with Metastatic Non-Clear Cell Renal Cell Carcinoma. <i>Oncologist</i> , 2020, 25, 186-188.	3.7	1
42	Macrophage HIF-1 α Is an Independent Prognostic Indicator in Kidney Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 4970-4982.	7.0	45
43	Association of SPOP Mutations with Outcomes in Men with De Novo Metastatic Castration-sensitive Prostate Cancer. <i>European Urology</i> , 2020, 78, 652-656.	1.9	64
44	Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <i>BRCA</i> Mutations among Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 2546-2555.	7.0	33
45	Olaparib for Metastatic Castration-Resistant Prostate Cancer. <i>New England Journal of Medicine</i> , 2020, 382, 2091-2102.	27.0	1,327
46	Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 2104-2110.	7.0	15
47	Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study. <i>Journal of Urology</i> , 2020, 204, 63-70.	0.4	32
48	Use and outcomes in men with metastatic castration-sensitive prostate cancer (mCSPC) treated with docetaxel in addition to androgen deprivation therapy (ADT): Analysis of real-world data in the United States (US).. <i>Journal of Clinical Oncology</i> , 2020, 38, e19322-e19322.	1.6	2
49	Cabozantinib (C) in combination with atezolizumab (A) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Results of Cohort 6 of the COSMIC-021 Study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 139-139.	1.6	18
50	Time to second progression (PFS2) in patients (pts) from TITAN with metastatic castration-sensitive prostate cancer (mCSPC) by first subsequent therapy (hormonal vs. taxane).. <i>Journal of Clinical Oncology</i> , 2020, 38, 82-82.	1.6	12
51	COVID-19 and androgen-targeted therapy for prostate cancer patients. <i>Endocrine-Related Cancer</i> , 2020, 27, R281-R292.	3.1	64
52	Treatment of metastatic renal cell carcinoma in older patients: A network meta-analysis. <i>Journal of Geriatric Oncology</i> , 2019, 10, 149-154.	1.0	14
53	Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study. <i>Lancet Oncology</i> , The, 2019, 20, 1518-1530.	10.7	69
54	Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer. <i>New England Journal of Medicine</i> , 2019, 381, 13-24.	27.0	904

#	ARTICLE	IF	CITATIONS
55	Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors. <i>JCO Precision Oncology</i> , 2019, 3, 1-23.	3.0	63
56	Management of Nonmetastatic Castration-Resistant Prostate Cancer: Recent Advances and Future Direction. <i>Current Treatment Options in Oncology</i> , 2019, 20, 14.	3.0	16
57	Cabozantinib in advanced non-clear-cell renal cell carcinoma: a multicentre, retrospective, cohort study. <i>Lancet Oncology</i> , The, 2019, 20, 581-590.	10.7	124
58	Treatment Decisions for Metastatic Clear Cell Renal Cell Carcinoma in Older Patients: The Role of TKIs and Immune Checkpoint Inhibitors. <i>Drugs and Aging</i> , 2019, 36, 395-401.	2.7	5
59	Targeting Endoglin to Treat Metastatic Renal Cell Carcinoma: Lessons from Osler-Weber-Rendu Syndrome. <i>Oncologist</i> , 2019, 24, 143-145.	3.7	3
60	Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2019, 37, 5076-5076.	1.6	11
61	Genetic testing for hereditary prostate cancer: Current status and limitations. <i>Cancer</i> , 2018, 124, 3105-3117.	4.1	72
62	Unclassified renal cell carcinoma: diagnostic difficulties and treatment modalities. <i>Research and Reports in Urology</i> , 2018, Volume 10, 205-217.	1.0	15
63	Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS42-TPS42.	1.6	4
64	Real world outcomes of nivolumab and cabozantinib in metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 615-615.	1.6	2
65	An open-label phase 1/2a study to evaluate the safety, pharmacokinetics, pharmacodynamics, and preliminary efficacy of TRC253, an androgen receptor antagonist, in patients with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS403-TPS403.	1.6	2
66	Phase II trial of neoadjuvant nivolumab with cisplatin and gemcitabine in muscle-invasive bladder cancer patients undergoing radical cystectomy.. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS528-TPS528.	1.6	2
67	Nomogram-based risk prediction of local and distant relapse after radical cystectomy, and role of perioperative chemotherapy, in patients with muscle-invasive bladder cancer (MIBC): A multicenter study.. <i>Journal of Clinical Oncology</i> , 2018, 36, 448-448.	1.6	0
68	Comparison of tumor mutational burden (TMB) in PBRM1/BAP1-based subsets of advanced renal cell carcinoma (aRCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 634-634.	1.6	1
69	Independent assessment of TP53 and PTEN as predictors of response to enzalutamide (ENZ) or abiraterone acetate (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 351-351.	1.6	0
70	Germline variant in SLCO2B1 and response to abiraterone acetate plus prednisone (AA) in men with metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 311-311.	1.6	0
71	Germline variant in HSD3B1 (1245 A>C) and response to abiraterone acetate plus prednisone (AA) in men with new onset metastatic castration-resistant prostate cancer (mCRPC).. <i>Journal of Clinical Oncology</i> , 2018, 36, 173-173.	1.6	0
72	Phase 1b trial of cabozantinib in combination with atezolizumab in patients with locally advanced or metastatic urothelial carcinoma (UC) or renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2018, 36, TPS541-TPS541.	1.6	0

#	ARTICLE	IF	CITATIONS
73	Targeting bacteroides in the stool microbiome and response to treatment (Rx) with first-line VEGFTKI in metastatic renal cell carcinoma (mRCC).. Journal of Clinical Oncology, 2018, 36, 584-584.	1.6	0
74	Comprehensive analysis of AR alterations in cell free DNA from prostate cancer patients.. Journal of Clinical Oncology, 2018, 36, 314-314.	1.6	0
75	Third-line Targeted Therapy in Metastatic Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium. European Urology, 2017, 71, 204-209.	1.9	65
76	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma. European Urology, 2017, 72, 557-564.	1.9	108
77	Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncology, 2017, 3, e170231.	7.1	9
78	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. Clinical Genitourinary Cancer, 2017, 15, 31-41.e4.	1.9	31
79	Cancer immunotherapy: A paradigm shift in the treatment of advanced urologic cancers. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 676-677.	1.6	9
80	PD-1 checkpoint inhibition: Toxicities and management. Urologic Oncology: Seminars and Original Investigations, 2017, 35, 701-707.	1.6	57
81	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. Immunotherapy, 2017, 9, 797-804.	2.0	30
82	Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 319-329.	3.8	20
83	Incidence of Immune-Related Adverse Events with Program Death Receptor-1- and Program Death Receptor-1 Ligand-Directed Therapies in Genitourinary Cancers. Frontiers in Oncology, 2017, 7, 56.	2.8	73
84	Reply to M.A.N. Åžendur et al and J. Michels. Journal of Clinical Oncology, 2017, 35, 123-123.	1.6	1
85	Current Treatment Landscape of Advanced Papillary Renal Cancer. Journal of Clinical Oncology, 2017, 35, 2981-2983.	1.6	13
86	Evolving Treatment Paradigm in Metastatic Renal Cell Carcinoma. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2017, 37, 319-329.	3.8	10
87	NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. Journal of the National Comprehensive Cancer Network: JNCCN, 2016, 14, 1213-1224.	4.9	93
88	Cabozantinib versus everolimus in advanced renal cell carcinoma (METEOR): final results from a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2016, 17, 917-927.	10.7	789
89	Randomized, Double-Blind, Placebo-Controlled Phase III Study of Tasquinimod in Men With Metastatic Castration-Resistant Prostate Cancer. Journal of Clinical Oncology, 2016, 34, 2636-2643.	1.6	77
90	Enzalutamide Versus Bicalutamide in Castration-Resistant Prostate Cancer: The STRIVE Trial. Journal of Clinical Oncology, 2016, 34, 2098-2106.	1.6	264

#	ARTICLE	IF	CITATIONS
91	Mutations in TSC1, TSC2, and MTOR Are Associated with Response to Rapalogs in Patients with Metastatic Renal Cell Carcinoma. <i>Clinical Cancer Research</i> , 2016, 22, 2445-2452.	7.0	193
92	Kidney Cancer, Version 3.2015. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2015, 13, 151-159.	4.9	198
93	FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma. <i>Cancer Imaging</i> , 2015, 15, 15.	2.8	35
94	Phase III, Randomized, Double-Blind, Multicenter Trial Comparing Orteronel (TAK-700) Plus Prednisone With Placebo Plus Prednisone in Patients With Metastatic Castration-Resistant Prostate Cancer That Has Progressed During or After Docetaxel-Based Therapy: ELM-PC 5. <i>Journal of Clinical Oncology</i> , 2015, 33, 723-731.	1.6	127
95	Cisplatin-Based First-Line Therapy for Advanced Urothelial Carcinoma After Previous Perioperative Cisplatin-Based Therapy. <i>Clinical Genitourinary Cancer</i> , 2015, 13, 178-184.	1.9	15
96	SWOG S0925: A Randomized Phase II Study of Androgen Deprivation Combined With Cixutumumab Versus Androgen Deprivation Alone in Patients With New Metastatic Hormone-Sensitive Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 1601-1608.	1.6	44
97	Clinical and Translational Assessment of VEGFR1 as a Mediator of the Premetastatic Niche in High-Risk Localized Prostate Cancer. <i>Molecular Cancer Therapeutics</i> , 2015, 14, 2896-2900.	4.1	15
98	Circulating Tumor Cell Counts Are Prognostic of Overall Survival in SWOG S0421: A Phase III Trial of Docetaxel With or Without Atrasentan for Metastatic Castration-Resistant Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2014, 32, 1136-1142.	1.6	268
99	Metastatic non-clear cell renal cell carcinoma treated with targeted therapy agents: Characterization of survival outcome and application of the International mRCC Database Consortium criteria. <i>Cancer</i> , 2013, 119, 2999-3006.	4.1	189
100	Missense mutation of the last nucleotide of exon 1 (G->C) of globin gene not only leads to undetectable mutant peptide and transcript but also interferes with the expression of wild allele. <i>Haematologica</i> , 2007, 92, 1715-1716.	3.5	8
101	Successful management of intra-abdominal hemorrhage in the presence of severe alcoholic liver disease with activated recombinant factor VII (rFVIIa; NovoSeven): a case report and review of the literature on approved and off-label use of rFVIIa. <i>Blood Coagulation and Fibrinolysis</i> , 2007, 18, 205-207.	1.0	9
102	Stimulation by serum of the Na ⁺ /H ⁺ antiporter in quiescent pig kidney epithelial (LLC-PK1) cells and role of the antiporter in the reinitiation of DNA synthesis. <i>Journal of Cellular Physiology</i> , 1987, 132, 173-177.	4.1	13